Back to top

Image: Bigstock

Genprex's (GNPX) Lead Cancer Drug Gets Second Fast Track Tag

Read MoreHide Full Article

Genprex, Inc. (GNPX - Free Report) announced that the FDA has granted a Fast Track designation to its lead product candidate, Reqorsa immunogene therapy, in combination with Merck’s (MRK - Free Report) PD-L1 inhibitor Keytruda, for treating patients with histologically-confirmed unresectable stage III or IV non-small cell lung cancer (“NSCLC”) whose disease progressed following treatment with Keytruda. This marks the second Fast Track designation for Reqorsa.

Merck’s biggest revenue generator, Keytruda, is approved for treating several types of cancer indications. The drug is also being studied for other types of cancer indications.

Genprex plans to initiate an open-label, multi-center phase I/II study – Acclaim-2 – which will evaluate the combo of Reqorsa plus Keytruda for the given indication in the first quarter of 2022.

Please note that data from pre-clinical studies have shown that Reqorsa in combination with Keytruda was more effective in increasing the survival of mice with a humanized immune system which had metastatic lung cancer than Keytruda alone.

Shares of Genprex were up 167.2% on Monday following the announcement of the above news. The stock has declined 15.3% in the past year compared with the industry’s decrease of 21.9%.

Zacks Investment ResearchImage Source: Zacks Investment Research

Fast Track designation is designed to facilitate the development and acceleration of the review of drugs to treat serious conditions and fill an unmet medical need or offer a potential advantage over the existing treatments.

In 2020, the FDA granted Fast Track designation to Reqorsa in combination with AstraZeneca’s (AZN - Free Report) Tagrisso for the treatment of patients with histologically confirmed unresectable stage III or IV NSCLC, with EGFR mutations that progressed following treatment with Tagrisso.

AstraZeneca’s newer drugs, mainly cancer medicines, Lynparza, Tagrisso and Imfinzi are driving its top line with strong sales growth.

Per the American Cancer Society, more than 235,000 new cases of lung cancer were reported in the United States in 2021, resulting in more than 131,000 deaths from the disease. Hence, if successfully developed and upon potential approval, Reqorsa might be able to tap into a market with significant potential while treating patients with late-stage NSCLC, besides driving growth for Genprex.

Zacks Rank & Stock to Consider

Genprex currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is vTv Therapeutics Inc. (VTVT - Free Report) , which has a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

vTv Therapeutics’ loss per share estimates have narrowed 2.9% for 2022, over the past 60 days.

vTv Therapeutics’ earnings have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


AstraZeneca PLC (AZN) - free report >>

Merck & Co., Inc. (MRK) - free report >>

vTv Therapeutics Inc. (VTVT) - free report >>

GENPREX (GNPX) - free report >>